[{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Borealis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Borealis Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Borealis Ventures"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Lung Cancer Initiative","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Lung Cancer Initiative","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Lung Cancer Initiative"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tolododekin Alfa","moa":"IL12RB","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tolododekin Alfa","moa":"IL12RB","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tolododekin Alfa","moa":"IL12RB","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Ankyra Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tolododekin Alfa is a Protein drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Skin Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 03, 2025

                          Lead Product(s) : Tolododekin Alfa

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tolododekin Alfa is a Protein drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 18, 2025

                          Lead Product(s) : Tolododekin Alfa

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 05, 2024

                          Lead Product(s) : ANK-101,Aluminium Hydroxide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 05, 2024

                          Lead Product(s) : ANK-101,Aluminium Hydroxide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tolododekin Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 15, 2023

                          Lead Product(s) : Tolododekin Alfa

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The collaboration aims to evaluate ANK-101, a novel first-in-class anchored IL-12 immunotherapy in combination with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab).

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          November 13, 2023

                          Lead Product(s) : ANK-101,Cemiplimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : ANK-101, an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, is locally delivered and retained in the tumor microenvironment for several weeks where it mediates recruitment and activation of effector immune cells.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 24, 2023

                          Lead Product(s) : ANK-101

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The collaboration aims to to evaluate ANK-101, a novel first-in-class anchored IL-12 immunotherapy, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) following the completion of phase I of ANK-101 alone in patients with advanced s...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          October 04, 2023

                          Lead Product(s) : ANK-101,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The collaboration will focus on the advancement of Ankyra’s lead product candidate, ANK-101, an IL-12-based locally administered immunotherapy, as a potential treatment for lung cancer.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          February 07, 2023

                          Lead Product(s) : ANK-101

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Lung Cancer Initiative

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Under the collaboration with NCI researchers to expand pre-clinical and clinical development of cytokine therapeutic ANK-101 and to combine the expertise to demonstrate the ability of immunotherapy platform to enhance the safety and efficacy of powerful ...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 18, 2022

                          Lead Product(s) : ANK-101

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : The Division of Cancer Treatment and Diagnosis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank